Medication Appropriateness in Elderly Patients Diagnosed with Pneumonia
Pharmaceutical SciencePharmacy Practice
DOI:
https://doi.org/10.22376/ijpbs/lpr.2022.12.6.P18-23Keywords:
Pneumonia, Comorbidities, Pharmacotherapeutic, Management, Medication Appropriateness Tools, PolypharmacyAbstract
Ageing is a natural process accompanied with compromised good health. Pneumonia is associated with several independent risk factors, including the severity of clinical presentation, age, comorbidities, and specific pathogens which increase the burden of morbidity, mortality in aged patients. This study was carried out to assess the appropriateness of therapy for pneumonia in elderly patients. A prospective, observational study was conducted from July 2018 to June 2021 in the department of pulmonary medicine of a tertiary care teaching hospital in Bangalore, India. A total of 90 elderly patients aged >65 years, diagnosed with pneumonia who fulfilled study criteria and consented to take part in the study were enrolled. A well designed and internally validated case report form was used to document the findings after a due approval from the Institutional Ethics Committee. Socio-demographic characteristics, prescribed medications and clinical characteristics were documented and analyzed. Out of the 90 elderly patients, 25.6% were male while 75.4% were female. The mean age of the participants was 70.03±5.26 (SD) years. Applying tools like START/STOPP criteria, Beers criteria and MAI index, it was found that, 16.7% were received incorrect dose, 12.22% received drug duplication, 3.3% received drug which was not indicated, 2.2% received drug which was not effective for that condition and in 1.1% patients did not receive drugs for required duration. The findings from this study provide the feedback to the healthcare team to ensure rational management of pneumonia in elderly patients and enable this vulnerable population with improved health related quality of life.
References
1097/MD.0000000000007929, PMID 28858118.
Stupka JE, Mortensen EM, Anzueto A, Restrepo MI. Community-acquired pneumonia in elderly patients. Aging Health. 2009;5(6):763-74. doi: 10.2217/ahe.09.74, PMID 20694055.
Cillóniz C, Rodríguez-Hurtado DR, Torres A. Characteristics and management of community-acquired pneumonia in the era of global aging. Med Sci (Basel). 2018;6(2):1-17. doi: 10.3390/medsci6020035, PMID 29710871.
Luna CM, Palma I, Niederman MS, Membriani E, Giovini V, Wiemken TL, et al. Impact of age and comorbidities in CAP mortality. Annals ATS. 2016 September;13(9):1519-26.
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 October 1;200(7):e45-67. doi: 10.1164/rccm.201908-1581ST, PMID 31573350.
Reddy CB, Nagkumar KP, Bindu MH, Reddy CM. Risk factors of community acquired pneumonia among the elderly population: A study in a semi urban area. IP Indian J Immunol Respir Med. 2021;6(2):125-29.
Torres OH, Munoz J, Ruiz D, Ris J, Gich I, Coma E, et al. J Am Geriatr Soc. 2004;52:1603-09.
Henig O, Kaye KS. Bacterial pneumonia in older adults. Infect Dis Clin N Am. 2017;31(4):689-713. doi: 10.1016/j.idc.2017.07.015, PMID 28916385.
Mangen MJJ, Huijts SM, Bonten MJM, Wit GAD. The impact of community-acquired pneumonia on the health-related quality of life in elderly. BMC Infect Dis. 2017;17(208):1-9.
Cillóniz C, Dominedò C, Pericàs JM, Rodriguez-Hurtado DR, Torres A. Community-acquired pneumonia in critically ill very old patients: a growing problem. Eur Respir Rev. 2020;29(155):190126. doi: 10.1183/16000617.0126-2019, PMID 32075858.
Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057-65. doi: 10.1136/thoraxjnl-2013-204282, PMID 24130229.
O’Connor JO, Adabavazeh B, Choi H, Khan A, Shah S, Shah S. Use of the STOPP and START criteria to address polypharmacy for elderly patients in University Hospital Lewisham Clinical Decisions Unit. HK J Emerg Med. 2021;28(2):79-84. doi: 10.1177/1024907919849358.
Awad A, Hanna O. Potentially inappropriate medication use among geriatric patients in primary care setting: A cross-sectional study using the Beers, STOPP, FORTA and MAI criteria. PLOS ONE. 2019;14(6):e0218174. doi: 10.1371/journal.pone.0218174, PMID 31194800.
Rakesh KB, Chowta MN, Shenoy AK, Shastry R, Pai SB. Evaluation of polypharmacy and appropriateness of prescription in geriatric patients: A cross-sectional study at a tertiary care hospital. Indian J Pharmacol. 2017;49(1):16-20. doi: 10.4103/0253-7613.201036, PMID 28458417.
Letter to the editor. J Am Geriatr Soc. 2006 April;54(4).
Karandikar YS, Chaudhari SR, Dalal NP, Sharma M, Pandit VA. Inappropriate prescribing in the elderly: A comparison of two validated screening tools. J Clin Gerontol Geriatr. 2013;4(4):109-14. doi: 10.1016/j.jcgg.2013.04.004.
de Oliveira Alves C, Schuelter-Trevisol F, Trevisol DJ. Beers criteria-based assessment of medication use in hospitalized elderly patients in Southern Brazil. J Fam Med Prim Care. 2014;3(3):260-5. doi: 10.4103/2249-4863.141628, PMID 25374866.
Dhyani V, Dhyani PM, Salimath G. Study of medication appropriateness during hospital stay and revisits in medicine department of tertiary care hospital. IOSR JPBS. November-December 2015;10(6):2278-3008.
Bernal SPB, Santiaguel J, Teodoro AL. Prevalence, demographic, clinical characteristics and outcomes of elderly patients with community acquired pneumonia admitted in a tertiary medical center: A retrospective cohort study. J Geriatr Med Gerontol;20217;7(3):1-9.
Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999 November;159(21):2562-72. doi: 10.1001/archinte.159.21.2562, PMID 10573046.
Hardin M, Silverman EK. Chronic obstructive pulmonary disease genetics: a review of the past and a look into the future. J COPD F. 2014;1(1):33-46.
Al Ameri MN, Makramalla E, Albur U, Kumar A, Rao P. Prevalence of poly-pharmacy in the elderly: implications of age, gender, co-morbidities and drug interactions. SOJ Pharm PharmSci. 2014;1(3):1-7.
Maher RL, Hanlon JT, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014 January;13(1):57-65. doi: 10.1517/14740338.2013.827660, PMID 24073682.
Morin L, Johnell K, Laroche ML, Fastbom J, Wastesson JW. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol. 2018;10:289-98. doi: 10.2147/CLEP.S153458, PMID 29559811.
Corsonello A, Abbatecola AM, Fusco S, Luciani F, Marino A, Catalano S, et al. The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly. Clin Microbiol Infect. 2015;21(1):20-6. doi: 10.1016/j.cmi.2014.09.011, PMID 25636922.
West LM, Cordina M, Cunningham S. Clinical pharmacist evaluation of medication inappropriateness in the emergency department of a teaching hospital in Malta. Pharm Pract. 2012 October-December;10(4):181-87. doi: 10.4321/s1886-36552012000400001, PMID 24155835.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Meenu Pandey, N.K. Meera
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
